[Upcoming Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne

Event Details

[Upcoming Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne

Time: January 18, 2017 from 1pm to 2pm
Location: Online Webinar - Eastern Time Zone
Website or Map: https://www.readytalk.com/join
Phone: 1.866.740.1260 -- Access code: 9449985
Event Type: webinar
Organized By: PPMD
Latest Activity: Jan 16, 2017

Export to Outlook or iCal (.ics)

Event Description

Wednesday, January 18 at 1:00PM EST

Please join Parent Project Muscular Dystrophy and ReveraGen BioPharma as we host a webinar Wednesday, January 18 at 1:00PM EST to discuss vamorolone (VBP15) clinical trials in Duchenne.

Dr. Eric Hoffman will present a brief history of the vamorolone program, explain current and anticipated clinical trials, and leave time for discussion and fielding of questions.


  • Abby Bronson
    Senior Vice President of Research Strategy, Parent Project Muscular Dystrophy
  • Eric Hoffman
    Dr. Hoffman identified the dystrophin protein as the cause of DMD in 1987, and has been a leading figure in DMD research since this time. He has over 500 research publications, and is on the Advisory Boards of DuchenneUK, Foundation to Eradicate Duchenne, CureDuchenne, Coalition to Cure Calpain 3 Foundation (C3), and Save Our Sons Foundation.  He has co-founded three venture philanthropy companies - ReveraGen BioPharma, AGADA BioSciences, and TRiNDS LLC, and is Associate Dean for Research at Binghamton University - SUNY School of Pharmacy and Pharmaceutical Sciences. In this webinar, he wears the hat of CEO, ReveraGen BioPharma.

To Participate:

  1. Visit ReadyTalk.com and use access code 9449985. (Be sure to test your computer beforehand)
  2. Audio Dial-In Information:
    • U.S. & Canada: Dial 1.866.740.1260 and use the Access Code 9449985
    • Outside the U.S. and Canada: Lookup your number

Submit Questions:

Please submit questions in advance to community@parentprojectmd.org, with “ReveraGen Webinar” in the subject line by noon on Monday, 1/16.

About Vamoralone:

Vamorolone is a new drug that has five different activities that may prove beneficial to Duchenne boys. It is a potent anti-inflammatory agent (similar to prednisone and deflazacort); It is a mineralocorticoid receptor antagonist, similar to epleronone, and may benefit Duchenne cardiac function; It is a membrane stabilizer, possibly counter-acting dystrophin deficiency at myofiber membranes; It is able to re-synchronize muscle regeneration, likely improving it.

These multiple aspects of efficacy must also be balanced with safety. With regards to side effects, vamorolone does not show many of the side effects seen with prednisone and deflazacort. Through blood biomarkers in adult volunteers, vamorolone does not show evidence of bone side effect, or metabolic side effects. In mouse studies, vamorolone did not show the stunting of growth seen in prednisolone-treated mice.

Learn more about Vamoralone on PPMD's DuchenneConnect site

Comment Wall


RSVP for [Upcoming Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne to add comments!

Join PPMD Community

Attending (3)

Need help using this community site? Visit Ning's Help Page.



© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service